Related Experiment Video
Updated: Nov 9, 2025

In vitro Measurements of Tracheal Constriction Using Mice
Published on: June 25, 2012
Meta-analysis of competitive antagonists in asthma treatment
Zhen Lei1, Qi Luo2, Weiyi Yang1
1Department of Respiratory and Critical Care Medicine, Affiliated Hospital of North Sichuan Medical College, Nanchong, China.
Background:
This meta-analysis was developed to explore the efficacy of using antagonists to the chemokine receptor of T helper type 2 (Th2) cells (CRTH2) in the treatment of asthma, so as to provide theoretical foundation and assistance for treatment of asthma.
Methods:
The Boolean logic search method (Boolean method) was adopted to search the publications in PubMed, Medline, and HowNet with "antagonist", "asthma", "competitive antagonist", and "efficiency" as the search terms. The publications taking placebo as control to treat the asthma were searched. The Review Manager software was applied for meta-analysis.
Results:
A total of 13 publications were included in this study, and most of them were low-risk bias (medium-high quality). The results of Meta-analysis showed that the treatment methods of the two groups of patients showed no statistically heterogeneous effects on the one-second forced expiratory volume (FEV1) in the maximum exhalation after the maximum deep inhalation (Chi2 =4.70, I2=0%, and P=0.79). The FEV1 of the control group was much lower than that of the experimental group (Z=3.61, P=0.0003). There was no great difference in the incidence of adverse events between the two groups (Z=0.46, P=0.64). No statistical heterogeneity (Chi2 =3.72, I2=0%, P=0.45) and difference (Z=1.57, P=0.12) were found in asthma exacerbation between the two groups. The asthma control questionnaire (ACQ) score of the control group was much lower than that of the experimental group (Z=3.20, P=0.001).
Conclusions:
Competitive antagonists of CRTH2 could effectively improve FEV1 and lower ACQ scores in patients with asthma, and were therefore effective in treating asthma.
Related Concept Videos
Antiasthma Drugs: Muscarinic Receptor Antagonists
Antimuscarinic agents compete with ACh for the same binding site on the muscarinic receptors. By binding to these receptors, they inhibit the downstream effects of ACh and block the parasympathetic...
Antiasthma Drugs: β2-Adrenoceptor Agonists
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce...
Combined Effects of Drugs: Antagonism
The most common type is receptor antagonism, where one drug acts as an antagonist to block the effects of another drug by...
Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Adrenergic Antagonists: Pharmacological Actions of ɑ-Receptor Blockers
α1-blockers: These drugs inhibit α1-adrenoceptors on smooth muscle cells, resulting in vasodilation. This vasodilation lowers blood pressure, making α1-blockers valuable in treating hypertension. Additionally,...
Adrenergic Antagonists: Chemistry and Classification of β-Receptor Blockers

